Sanofi MenQuadfi wins EU approval for use in infants from six weeks

• The European Commission extended the EU label for Sanofi’s MenQuadfi meningococcal vaccine to include infants from six weeks of age.
• MenQuadfi was previously cleared for use from 12 months and older.
• The broader indication targets invasive meningococcal disease caused by serogroups A, C, W, and Y.
• The decision follows a positive CHMP opinion issued on June 25, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-336497), on August 06, 2026, and is solely responsible for the information contained therein.